TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05536440
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV or SC
Study: NCT06527846
Drug: JARDIANCE®
Approvals — FDA: no, EMA: no, PMDA: no
Description: JARDIANCE®
Study: NCT06566508
Drug: Calcium Hydroxide Intracanal medication
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium Hydroxide Intracanal medication
Study: NCT03180450
Drug: conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drug and usage will be determined based on patient's condition, including milrinone, furosemide, beta-blocker blues, Angiotensin-Converting Enzyme Inhibitors (ACEI), angiotension receptor blocker (ARB), or antiplatelet aggregation etc.
Study: NCT05886335
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Time of administration
Study: NCT03806478
Drug: APH-1105
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigational drug product, APH-1105 is a sterile, pyrogen-free lyophilized powder intended for intranasal administration.
Study: NCT06564272
Drug: KC1036
Approvals — FDA: no, EMA: no, PMDA: no
Description: For patients weighing between 30 kg and less than 50 kg, administer 40 mg QD of KC1036. For patients weighing between 50 kg and less than 70 kg, administer 50 mg QD of KC1036. For patients weighing 70 kg or more, administer 60 mg QD of KC1036. 4 weeks as a cycle.
Study: NCT05093907
Drug: BEY1107
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administer once daily, PO, 3-week continuous dose.
Study: NCT05778227
Drug: Ethylene Diamine Tetra Acetic acid
Normalized name: Ethylene-diamine
DrugBank: Ethylenediamine (DB14189)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Final irrigation will be done with 5ml of EDTA for 1min which is the gold standard and compare it with experimental irrigants.
Study: NCT05778227
Drug: smearOFF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Final irrigation of root canal treatment procedure will be done with 5ml of smearOFF for 1min.
Study: NCT05778227
Drug: Maleic acid
Normalized name: Maleic Acid
DrugBank: Maleic acid (DB04299)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Final irrigation of root canal treatment procedure will be done with 5ml of maleic acid for 1min.
Study: NCT04918147
Drug: acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premedication administered orally, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
Study: NCT05624710
Drug: INCB054707
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB054707 75 mg will be administered orally on Day 1.
Study: NCT06641089
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06105671
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants are administered placebo
Study: NCT05974423
Drug: Tylenol, Ibuprofen, and Oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: A script for these three medications will be provided
Study: NCT05974423
Drug: Tylenol and Ibuprofen only
Approvals — FDA: no, EMA: no, PMDA: no
Description: A script for only these two medications will be provided initially following surgery. Should the patient need stronger medication for adequate pain control, the on-call physician will provide a script for oxycodone
Study: NCT06378957
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (cellulose) administered via capsule
Study: NCT05739942
Drug: [177Lu]Lu-NeoB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiopharmaceutical solution for infusion
Study: NCT05739942
Drug: [68Ga]Ga-NeoB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Either provided as Kit for the radiopharmaceutical preparation of \[68Ga\]Ga-NeoB or as ready to use radiopharmaceutical solution for injection
Study: NCT05249959
Drug: Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at standard dose (R-BAC, Rituximab - Bendamustine, Ara-C))
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Induction phase (cycle 1-2 of R-BAC every 28 days according to the following schedule):~* Rituximab 375 mg/m2 i.v. Day 1~* Bendamustine 70 mg/m2, Days 2 and 3~* Cytarabine 500 mg/m2, Day 2-4~After restaging at the End of Induction (EOI) patients with CR (complete response), PR (partial response) or SD (stable disease) will receive:~CONSOLIDATION PHASE:~* 2 infusions of loncastuximab tesirine at a dose of 150 microgram/kg every three weeks followed by~* 2 infusions of loncastuximab tesirine at a dose of 75 microgram/kg every three weeks
Study: NCT05359211
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06157502
Drug: Shuxuening Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receiving 20 ml Shuxuening injection plus 250ml 0.9% sodium chloride injection, intravenous drip once a day, for 10-14 days
Study: NCT05288374
Drug: Celecoxib 100 mg
Normalized name: celecoxib 100 MG
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administering Celecoxib 100 mg (Celebrex) regularly every 12 hours for 3 days starting at 6 in the morning on the day of surgery
Study: NCT05288374
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administering placebo regularly every 12 hours for 3 days starting at 6 in the morning on the day of surgery
Study: NCT04904588
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV pre-transplant as part of conditioning regimen
Study: NCT05563246
Drug: LY3473329
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT05563246
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT06649630
Drug: NNC0442-0344 A
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAD: NNC0442-0344 A will be administered intravenously.~MAD: NNC0442-0344 A will be administered orally.
Study: NCT06649630
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAD: Placebo will be administered intravenously.~MAD: Placebo will be administered orally.
Study: NCT04987944
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching active drug
Study: NCT06001177
Drug: KAN-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose KAN-101 Intravenous (IV) Infusion
Study: NCT06001177
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Intravenous (IV) Infusion
Study: NCT05860010
Drug: Epinephrine injection
Normalized name: epinephrine Injection
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will be placed on left lateral position and drug will be given the caudal space
Study: NCT04725357
Drug: Meloxicam 15 mg
Normalized name: meloxicam 15 MG
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive a prescription of 20 pills of 15 mg Meloxicam after surgery
Study: NCT05558007
Drug: Oral Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of a placebo pill
Study: NCT05558007
Drug: Topical Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 1.5 mL of placebo
Study: NCT05975047
Drug: LIV001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A- Participants will receive single dose of 280mg capsule on day 1 under fasting conditions; Part B- Participants will receive multiple doses of 280mg capsule from day 1 to day 14 under fasting conditions;
Study: NCT05975047
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo across Part A and B of the study
Study: NCT05991583
Drug: IBB0979
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBB0979 should be subcutaneous injected，qw
Study: NCT06506305
Drug: FB1001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal (IVT) injection
Study: NCT05542407
Drug: ONC201
Approvals — FDA: no, EMA: no, PMDA: no
Description: 375 mg once weekly - 625 mg ONC201 will be administered orally, once or twice weekly.
Study: NCT05451407
Drug: TQB2618 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humanized IgG4 mab targeting TIM-3
Study: NCT06309394
Drug: INCB099280
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB099280 will be administered orally, followed approximately 10 minutes later by an oral dose solution of radiolabeled INCB099280.
Study: NCT06417476
Drug: Calcium Formate
Normalized name: Calcium formate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/m² iv drip over 2 hours on day 1, repeated every 14 days.
Study: NCT06417476
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2400 mg/m² iv drip over 48 hours on day 1-2, repeated every 14 days.
Study: NCT06417476
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 825 mg/m² twice daily administered orally and concurrently with radiation therapy for 5 days per week.
Study: NCT05462522
Drug: RO7303509
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7303509 will be administered as SC injection monthly, as specified in each treatment group.
Study: NCT05462522
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7303509 matching placebo will be administered as SC injection monthly, during the MAD stage.
Study: NCT06201676
Drug: Ketorolac Injection
Normalized name: ketorolac Injection
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits analgesic activity in animal models. The mechanism of action of ketorolac, like that of other NSAIDs, is not completely understood but may be related to prostaglandin Reference ID: 3281582 3 synthetase inhibition. The biological activity of ketorolac tromethamine is associated with the S-form. Ketorolac tromethamine possesses no sedative or anxiolytic properties.
Study: NCT06653244
Drug: Injection
Normalized name: Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: dexmedimidine infusion
Study: NCT05190562
Drug: Zinc Sulfate 110 MG (Zinc 25 MG) Oral Tablet
Normalized name: zinc sulfate 110 MG (zinc 25 MG) Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc sulfate is an inorganic compound. It is used as a dietary supplement to treat zinc deficiency and to prevent the condition in those at high risk
Study: NCT05919147
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will have the same appearance as the active drug.
Study: NCT05207176
Drug: DWP16001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects should fast except for drinking water after 10 p.m. in order to maintain a fasting state for at least 10 hours before administration. On dosing days (5d to 10d), except for 1d and 11d, breakfast can be consumed from about 1 hour after administration of the clinical trial drug. Subjects should swallow the investigational drug whole with 150 mL of water, and should not chew the drug before swallowing. Subjects should fast for 4 hours after dosing, and can drink water freely from 2 hours after dosing.
Study: NCT04923607
Drug: TQC2731
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQC2731 injection
Study: NCT04923607
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo with no active ingredients
Study: NCT05631678
Drug: Rifampicin; ASK120067
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take ASK120067 tablets orally once on the first day at 160mg in fast condition;Take rifampicin capsules orally once on the days 8 to 17 at 600mg in fast condition, and a combination of 160mg ASk120067 and 600mg rifampicin were administrated on the 15th day in fast condition.
Study: NCT05948553
Drug: Intervention A Fluoxetine Hydrochloride (HCl)
Normalized name: Fluoxetine Hydrochloride
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine will be administered at 10 to 60 mg daily. The initial dose for all participants will be 10 mg daily for 1 week, then increased to 20 mg daily for 2 weeks, then increased to 40 mg daily for 2 weeks, then increased to 60 mg daily for the remainder of the trial. One reduction in dose due to tolerability will be allowed. When a participant's dose is decreased due to tolerability, the dose will not be increased.
Study: NCT05948553
Drug: Intervention A Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A matching placebo will be administered at 10 to 60 mg daily in the same regimen as the intervention.
Study: NCT06310590
Drug: NRT6003 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective internal radiation therapy (SIRT) with TareSphere
Study: NCT06280976
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: high intensity statin (eg atorvastatin 80 mg daily)
Study: NCT04221750
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally starting at 500 mg (one tablet) taken orally once a day with meals. After a week, the dose of placebo will be increased to 1000 mg (two tablets) daily. After another week, the dose of placebo will be increased to 1500 mg (three tablets) daily.
Study: NCT06701344
Drug: Go-CHOP (Golidocitinib plus Cyclophosphamide, vincristine, doxorubicin and prednisone)
Normalized name: Go-dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction Treatment:~Golidocitinib:150mg QD Cyclophosphamide:750mg/m2，d1 vincristine:1.4mg/m2，d1(max 2mg) doxorubicin:50mg/m2，d1 Prednisone:60mg/m2 (max 100mg)，d1-d5 Every 21 days
Study: NCT05238961
Drug: [18F]DPA-714
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational PET Tracer \[18F\]DPA-714
Study: NCT06689917
Drug: JY231 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upon enrolment, leukapheresis will be performed and patients will receive 3-5 days of fludarabine and cyclophosphamide lymphodepleting therapy followed by an intravenous infusion of the JY231.
Study: NCT06005324
Drug: TFHX Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with paclitaxel, fluorouracil (5FU), and hydroxyurea given in combination with radiation therapy. Investigator will choose the appropriate chemotherapy backbone to be given during CRT.
Study: NCT05196711
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the SAD phase, the proposed doses will be increased gradually. Each cohort will consist of 8 subjects, with 2 subjects randomly assigned to placebo~In the MAD phase, the treatment will be administered once a day for 14 consecutive days. Each cohort will consist of 10 subjects, with 2 subjects randomly assigned to placebo
Study: NCT06702566
Drug: PD-1 and PD-L1 inhibitor
Normalized name: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 inhibitor includes pembrolizumab，Nivolumab，Sintilimab，tislelizumab，Triplimab，Camrelizumab, Serplulimab.~PD-L1 inhibitor includes durvalumab,Atezolizumab,Adebrelimab,Envafolimab.
Study: NCT06702566
Drug: Targeted drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted drugs includes EGFR-TKIs,ALK-TKIs,Multitargeted Tyrosine Kinase Inhibitors, VEGF antibody, EGFR antibody, antibody-drug conjugates drugs
Study: NCT04590417
Drug: Estradiol valerate 2 mg, cyproterone acetate 25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: The entire study period will be approximately 1 year, which will include around 2 months of document preparation, 5 months of recruitment, 3 months of follow-up, and 2 months of data analysis.
Study: NCT04851093
Drug: TCM granule plus conventional drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive conventional drug according to 2020 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Medicine Diagnosis Treatment Guidelines.~Yiqiwenfei granule for qi deficiency and internal cold fluid syndrome.~Fuzhengqinghua granule for qi and yin deficiency and unclean phlegm heat syndrome.~Fuzhengzaohua granule for lung and spleen qi deficiency and phlegm-damp amassing in lung syndrome.~TCM granule (Jiangyin Tian Jiang Pharmaceutical Co.,Ltd, 10g/packet) will be administered twice daily for 8 weeks.
Study: NCT04851093
Drug: TCM placebo granule plus conventional drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive conventional drug according to 2020 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Medicine Diagnosis Treatment Guidelines.~Placebo Yiqiwenfei granule for qi deficiency and internal cold fluid syndrome.~Placebo Fuzhengqinghua granule for qi and yin deficiency and unclean phlegm heat syndrome.~Placebo Fuzhengzaohua granule for lung and spleen qi deficiency and phlegm-damp amassing in lung syndrome.~TCM placebo granule (Jiangyin Tian Jiang Pharmaceutical Co.,Ltd, 10g/packet) will be administered twice daily for 8 weeks.~The appearance, weight, color and odor of the preparation are the same as those of experimental group.~The placebo granule consists of dextrin, bitter and 5% of the TCM granule.
Study: NCT06064006
Drug: NNC0487-0111
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC0487-0111 will be administered as a subcutaneous (s.c. under the skin) injection.
Study: NCT06064006
Drug: Placebo (NNC0487-0111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching NNC0487-0111 will be administered as a subcutaneous (s.c. under the skin) injection.
Study: NCT05918133
Drug: PM8002
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT04788615
Drug: First line DMT
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: any one of these based on availability at country given as First line DMT Glatiramer acetate 20mg or 40mg or Interferon 22µg or 0.25mg or Peg-Interferon beta-1a 63µg or 125µg or Teriflunomide 14mg or Dimethyl fumarate 120mg or 240mg or Diroximel fumarate 231mg or 462mg
Study: NCT05341583
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 225 mg once daily until disease recurrence or up to 2 years, whichever occurs earlier.
Study: NCT05634720
Drug: HA Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive the interventional treatment, which is neoadjuvant HA chemotherapy (FUDR/oxaliplatin delivered via the Hepatic Artery).
Study: NCT05565105
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide: 60 mg/kg/day x 2 or Fludarabine 25 mg/m\^2 x 5 if cyclophosphamide is contraindicated
Study: NCT05309655
Drug: Adenosine Stress Cardiac Magnetic Resonance Imaging
Normalized name: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine stress CMR test with contrast to include cardiovascular structural and functional measures including myocardial blood flow through quantitative perfusion mapping. Participants will have 3 stress tests as a part of this research. These tests will happen when at the beginning of the study, and then every year for 2 years.
Study: NCT06308874
Drug: Bmg dose administration group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally, Bmg tablet single administration
Study: NCT06308874
Drug: Bmg dose administration group- Placebo
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally, Placebo Bmg tablet single administration
Study: NCT05098275
Drug: DA-5210 10/500mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose administration (one tablet once a day)
Study: NCT05098275
Drug: DA-5210-R 10/500mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose administration (one tablet once a day)
Study: NCT05586048
Drug: Yiqi Fumai Lyophilized Injection(YQFM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intervention was involved, but patients will be divided into exposed or non-exposed groups based on whether they received YQFM
Study: NCT05225831
Drug: Cyclophosphamide,Fludarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given
Study: NCT05347147
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is supplied as 2 parts (visually identical to the Presendin vial and pre-filled diluent syringe). The drug part will exclude the active pharmaceutical ingredient (exenatide acetate) and the diluent part will be the same as the active treatment diluent. The drug part is suspended in the diluent part solution and administered SC as a suspension.
Study: NCT05658107
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05974293
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo is a matching oromucosal spray that is identical to the investigational study product in terms of packaging, labelling, schedule of administration, dosing instructions, and appearance.
Study: NCT05926492
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1) High-dose methotrexate : 8-12 g/m2 (MTX chemotherapy requires blood drug concentration monitoring), day 1 and 8; 2) Doxorubicin 60 mg/m2 or liposomal doxorubicin 45mg/ m2, day 17; 3) Cisplatin: 100 mg/m2, day 15;4) Ifosfamide; 2.5 g/m2, day 8-12.~The above drugs were used in turn, and 30 days were regarded as a treatment cycle.
Study: NCT05380882
Drug: TQB2930 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2930 is an anti-HER2 bispecific antibody.
Study: NCT05260541
Drug: 60 mg PRAX-114 or 40 mg PRAX-114
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily oral treatment for 4 weeks
Study: NCT05260541
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily oral treatment for 4 weeks
Study: NCT05260541
Drug: 40 mg PRAX-114
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily oral treatment for 8 weeks
Study: NCT05943158
Drug: myoinositol and folic acid
Normalized name: ferrous fumarate and folic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: The pregnant women were given myoinositol+folic acid starting from initial examination of pregnancy until 24-28 weeks of gestation (time of oral glucose tolerance test)
Study: NCT05943158
Drug: folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The pregnant women were given only folic acid starting from initial examination of pregnancy until 24-28 weeks of gestation (time of oral glucose tolerance test)
Study: NCT05960708
Drug: YH35324
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of YH35324
Study: NCT05960708
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of None of active ingredient
Study: NCT05020730
Drug: PTM-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTM-001 (400 mg) every day for 12 weeks
Study: NCT05198245
Drug: Various
Normalized name: VARIOUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various